ClinicalTrials.gg

Program

RBD7022

A development code. Also written as “RBD7022 injection”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias, led by 2 companies.

Furthest: phase 1, since Jul 10, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 1since Jul 10, 2025Jul 10, 2025none ahead
Suzhou Ribo Life Science10 open or runningphase 1since May 21, 2023May 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2023First study: phase 1 study in HyperlipidemiasNew to Suzhou Ribo Life ScienceSuzhou Ribo Life Science · NCT05912296 · 80 enrolled · China
  2. Jul 10, 2025Qilu Pharmaceutical's first study: phase 1 study in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-CNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07074236 · 48 planned · China

TargetBeta

PCSK9 →read by rule
“RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07074236Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C · China1Not yet recruitingQilu PharmaceuticalJan 202648
NCT05912296Hyperlipidemias · China1CompletedSuzhou Ribo Life ScienceMar 4, 202580

How it is read

Names in the registry

  • “RBD7022”, 2 entries
  • “RBD7022 injection”, 1 entry

Codes read as this program: RBD7022.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.